Trillium Therapeutics (NASDAQ:TRIL) has jumped 43.6% postmarket after reports that Gilead Sciences approached Forty Seven (NASDAQ:FTSV) with a takeover offer.
Trillium is working on a medicine similar to that
in Forty Seven’s lead program (magrolimab), a monoclonal antibody
against the CD47 receptor.
https://seekingalpha.com/news/3546883-trilliumplus-44-after-report-of-possible-forty-seven-takeover
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.